On May 28, 2019, the United States Department of Agriculture (the “USDA”) and the Office of the General Counsel (the “GC”) issued a legal opinion on the status of hemp following the passage of the 2018 Farm Bill. The opinion confirms: first, hemp must be produced under the 2014 Farm Bill until the USDA creates federal regulations or endorses a State program, and second, all hemp produced under the 2014 Farm Bill is protected by…
Canna Compliance West is a unique gathering of policy-makers, attorneys, proprietors, and growers. They all come together annually to discuss the current legal regulations on cannabis and the state of the market. Husch Blackwell’s Steve Levine will be the keynote speaker for the conference on May 30, 2019. Steve will be giving a presentation called, “Where are We? The Latest Scorecard on State Regs and Overall Market Evolution.” In his presentation he will address the current state of cannabis and…
Trademark practitioners, hemp producers, and hemp-derived product manufacturers have long struggled with the clash of federal and state law regarding protection of trademarks with the United States Patent and Trademark Office (USPTO). Historically, the USPTO has refused registration of marks that include cannabis, hemp, CBD or derived products on the basis that these marks were unable to have lawful use in commerce under existing federal law. These waters became even murkier after the passage of the Agricultural…
Last Friday, Husch Blackwell’s Steve Levine talked with James Dornbrook of the Kansas City Business Journal about the unclear rules and regulations of the medical marijuana business in Missouri. With the state deadline for accepting applications Aug. 3, there is no way a comprehensive set of regulations will all be ready in time. Another area of concern is the tricky (and sketchy) subject of leases. Read the article to find out why Levine focuses on helping…
On Wednesday, April 3, 2019, the U.S. Food and Drug Administration (FDA) announced plans to hold a meeting to discuss its regulatory approach to products that contain cannabis and cannabis-derived compounds, including cannabidiol (CBD). The public hearing, which is scheduled to be held on May 31, 2019, is intended to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis and cannabis-derived compounds. Husch Blackwell attorneys…